High-dosage tamoxifen as neoadjuvant treatment in minimally invasive surgery for dupuytren disease in patients with a strong predisposition toward fibrosis: A randomized controlled trial

Journal of Bone and Joint Surgery

Volumn 96, Issue 8, 2014, Pages 655-662

  Degreef, Ilse ^a   Tejpar, Sabine ^a   Sciot, Raf ^a   De Smet, Luc ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ADJUVANT THERAPY; ADULT; APPENDICITIS; ARTICLE; CARPAL TUNNEL SYNDROME; CONTROLLED STUDY; DISEASE PREDISPOSITION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MEGADOSE; DRUG WITHDRAWAL; DUPUYTREN CONTRACTURE; FEMALE; FIBROSIS; FLEXOR TENDON; GRANULOMA; HEMICOLECTOMY; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMALLY INVASIVE SURGERY; NERVE COMPRESSION; PATIENT MONITORING; PATIENT SATISFACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ANTI-INFLAMMATORY AGENTS; DOUBLE-BLIND METHOD; DUPUYTREN CONTRACTURE; FASCIA; FEMALE; FIBROSIS; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PATIENT SATISFACTION; PROSPECTIVE STUDIES; RANGE OF MOTION, ARTICULAR; SURGICAL PROCEDURES, MINIMALLY INVASIVE; TAMOXIFEN;

EID: 84898969656     PISSN: 00219355     EISSN: 15351386     Source Type: Journal    
DOI: 10.2106/JBJS.L.01623     Document Type: Article

References (41)

1. Badalamente MA, Hurst LC, Hentz VR. Collagen as a clinical target: nonoperative treatment of Dupuytren's disease. J Hand Surg Am. 2002 Sep;27(5):788-98.
2. Degreef I, De Smet L. Dupuytren's disease: a predominant reason for elective finger amputation in adults. Acta Chir Belg. 2009 Jul-Aug;109(4):494-7.
3. Hayton MJ, Gray ICM. Dupuytren's contracture: a review. Curr Orthop. 2003;17(1):1-7. (Pubitemid 36358792)
4. Abe Y, Rokkaku T, Ofuchi S, Tokunaga S, Takahashi K, Moriya H. An objective method to evaluate the risk of recurrence and extension of Dupuytren's disease. J Hand Surg Br. 2004 Oct;29(5):427-30. (Pubitemid 39186085)
5. Norotte G, Apoil A, Travers V. A ten years follow-up of the results of surgery for Dupuytren's disease. A study of fifty-eight cases. Ann Chir Main. 1988;7(4):277-81. (Pubitemid 19043660)
6. Rombouts JJ, Noël H, Legrain Y, Munting E. Prediction of recurrence in the treatment of Dupuytren's disease: evaluation of a histologic classification. J Hand Surg Am. 1989 Jul;14(4):644-52.
7. Bulstrode NW, Jemec B, Smith PJ. The complications of Dupuytren's contracture surgery. J Hand Surg Am. 2005 Sep;30(5):1021-5. (Pubitemid 41337932)
8. Citron ND, Nunez V. Recurrence after surgery for Dupuytren's disease: a randomized trial of two skin incisions. J Hand Surg Br. 2005 Dec;30(6):563-6. Epub 2005 Sep 6.
9. Degreef I, Boogmans T, Steeno P, De Smet L. Segmental fasciectomy in Dupuytren disease. Lowest recurrence rates in patient's perception. Eur J Plast Surg. 2009;32:185-8.
10. van Rijssen AL, Gerbrandy FS, Ter Linden H, Klip H, Werker PM. A comparison of the direct outcomes of percutaneous needle fasciotomy and limited fasciectomy for Dupuytren's disease: a 6-week follow-up study. J Hand Surg Am. 2006 May-Jun;31(5):717-25.
11. Degreef I, De Smet L, Sciot R, Cassiman JJ, Tejpar S. Beta-catenin overexpression in Dupuytren's disease is unrelated to disease recurrence. Clin Orthop Relat Res. 2009 Mar;467(3):838-45. Epub 2008 Oct 29.
12. Wilbrand S, Flodmark Ch, Ekbom A, Gerdin B. Activation markers of connective tissue in Dupuytren's contracture: relation to postoperative outcome. Scand J Plast Reconstr Surg Hand Surg. 2003;37(5):283-92. (Pubitemid 37352420)
13. Degreef I, De Smet L. Risk factors in Dupuytren's diathesis: is recurrence after surgery predictable? Acta Orthop Belg. 2011 Feb;77(1):27-32.
14. Degreef I, Tejpar S, De Smet L. Improved postoperative outcome of segmental fasciectomy in Dupuytren disease by insertion of an absorbable cellulose implant. J Plast Surg Hand Surg. 2011 Jun;45(3):157-64.
15. Badalamente MA, Sampson SP, Hurst LC, Dowd A, Miyasaka K. The role of transforming growth factor beta in Dupuytren's disease. J Hand Surg Am. 1996 Mar;21(2):210-5. (Pubitemid 26099450)
16. Rehman S, Goodacre R, Day PJ, Bayat A, Westerhoff HV. Dupuytren's: a systems biology disease. Arthritis Res Ther. 2011;13(5):238. Epub 2011 Sep 12.
17. Tse R, Howard J, Wu Y, Gan BS. Enhanced Dupuytren's disease fibroblast populated collagen lattice contraction is independent of endogenous active TGF-beta2. BMC Musculoskelet Disord. 2004 Nov 12;5(1):41. Epub 2004 Nov 12.
18. Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol. 2002 May;3(5):349-63. (Pubitemid 34619269)
19. Varallo VM, Gan BS, Seney S, Ross DC, Roth JH, Richards RS, McFarlane RM, Alman B, Howard JC. Beta-catenin expression in Dupuytren's disease: potential role for cell-matrix interactions in modulating beta-catenin levels in vivo and in vitro. Oncogene. 2003 Jun 12;22(24):3680-4. (Pubitemid 36760730)
20. Kuhn MA, Wang X, Payne WG, Ko F, Robson MC. Tamoxifen decreases fibroblast function and downregulates TGF(beta2) in Dupuytren's affected palmar fascia. J Surg Res. 2002 Apr;103(2):146-52. (Pubitemid 34948495)
21. Bourouma R, Chevet D, Michel F, Cercueil JP, Arnould L, Rifle G. Treatment of idiopathic retroperitoneal fibrosis with tamoxifen. Nephrol Dial Transplant. 1997 Nov;12(11):2407-10. (Pubitemid 27474629)
22. Ergun I, Keven K, Canbakan B, Ekmekci Y, Erbay B. Tamoxifen in the treatment of idiopathic retroperitoneal fibrosis. Int Urol Nephrol. 2005;37(2):341-3. (Pubitemid 41349202)
23. Hansmann A, Adolph C, Vogel T, Unger A, Moeslein G. High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer. 2004 Feb 1;100(3):612-20. (Pubitemid 38128287)
24. Bauernhofer T, Stöger H, Schmid M, Smola M, Gürtl-Lackner B, Höfler G, Ranner G, Reisinger E, Samonigg H. Sequential treatment of recurrent mesenteric desmoid tumor. Cancer. 1996 Mar 15;77(6):1061-5. (Pubitemid 26080895)
25. Nóvoa FJ, Boronat M, Carrillo A, Tapia M, Díaz-Cremades J, Chirino R. Effects of tamoxifen on lipid profile and coagulation parameters in male patients with pubertal gynecomastia. Horm Res. 2002;57(5-6):187-91. (Pubitemid 34621650)
26. Barbier O, Hoogmartens M. Evidence-based medicine in orthopaedics. Acta Orthop Belg. 2004 Apr;70(2):91-7. (Pubitemid 38620657)
27. Moher D, Schulz KF, Altman D; CONSORT Group (Consolidated Standards of Reporting Trials). The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA. 2001 Apr 18;285(15):1987-91. (Pubitemid 32366951)
28. Plint AC, Moher D, Morrison A, Schulz K, Altman DG, Hill C, Gaboury I. Does the CONSORT checklist improve the quality of reports of randomised controlled trials? A systematic review. Med J Aust. 2006 Sep 4;185(5):263-7. (Pubitemid 44382877)
29. Gauglitz GG, Korting HC, Pavicic T, Ruzicka T, Jeschke MG. Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies. Mol Med. 2011 Jan-Feb;17(1-2):113-25. Epub 2010 Oct 5.
30. Hughes-Davies L, Caldas C, Wishart GC. Tamoxifen: the drug that came in from the cold. Br J Cancer. 2009 Sep 15;101(6):875-8. Epub 2009 Aug 11.
31. Moermans JP. Segmental aponeurectomy in Dupuytren's disease. J Hand Surg Br. 1991 Aug;16(3):243-54.
32. Larson D, Jerosch-Herold C. Clinical effectiveness of post-operative splinting after surgical release of Dupuytren's contracture: a systematic review. BMC Musculoskelet Disord. 2008;9:104. Epub 2008 Jul 21.
33. Tubiana R, Michon J, Thomine JM. Scheme for the assessment of deformities in Dupuytren's disease. Surg Clin North Am. 1968 Oct;48(5):979-84.
34. Lintermans A, Laenen A, Van Calster B, Van Hoydonck M, Pans S, Verhaeghe J, Westhovens R, Henry NL, Wildiers H, Paridaens R, Dieudonné AS, Leunen K, Morales L, Verschueren K, Timmerman D, De Smet L, Vergote I, Christiaens MR, Neven P. Prospective study to assess fluid accumulation and tenosynovial changes in the aromatase inhibitor-induced musculoskeletal syndrome: 2-year follow-up data. Ann Oncol. 2013 Feb;24(2):350-5. Epub 2012 Oct 4.
35. Agee JM, Goss BC. The use of skeletal extension torque in reversing Dupuytren contractures of the proximal interphalangeal joint. J Hand Surg Am. 2012 Jul;37(7):1467-74. Epub 2012 May 30.
36. Sauerland S, Davis TR. The Consolidated Standards of Reporting Trials (CONSORT): better presentation of surgical trials in the Journal of Hand Surgery. J Hand Surg Br. 2004 Dec;29(6):621-4. (Pubitemid 39497207)
37. Torrance GW, Feeny D, Furlong W. Visual analog scales: do they have a role in the measurement of preferences for health states? Med Decis Making. 2001 Jul-Aug;21(4):329-34. (Pubitemid 32652496)
38. Degreef I, Vererfve PB, De Smet L. Effect of severity of Dupuytren contracture on disability. Scand J Plast Reconstr Surg Hand Surg. 2009;43(1):41-2.
39. Jerosch-Herold C, Shepstone L, Chojnowski A, Larson D. Severity of contracture and self-reported disability in patients with Dupuytren's contracture referred for surgery. J Hand Ther. 2011 Jan-Mar;24(1):6-10; quiz 11. Epub 2010 Oct 16.
40. Bunker TD, Anthony PP. The pathology of frozen shoulder. A Dupuytren-like disease. J Bone Joint Surg Br. 1995 Sep;77(5):677-83.
41. Smith SP, Devaraj VS, Bunker TD. The association between frozen shoulder and Dupuytren's disease. J Shoulder Elbow Surg. 2001 Mar-Apr;10(2):149-51. (Pubitemid 33602085)